Day One Biopharmaceuticals Stock Today
| DAWN Stock | USD 13.72 0.18 1.33% |
Performance1 of 100
| Odds Of DistressOver 51
|
Day One is selling at 13.72 as of the 28th of November 2024; that is 1.33 percent increase since the beginning of the trading day. The stock's open price was 13.54. Day One has 51 percent odds of going through some form of financial distress in the next two years and did not have a very good performance for investor during the last 90 trading days. Equity ratings for Day One Biopharmaceuticals are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 29th of October 2024 and ending today, the 28th of November 2024. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 27th of May 2021 | Category Healthcare | Classification Health Care |
Day One Biopharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genetically defined cancers. Day One Biopharmaceuticals, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California. The company has 100.85 M outstanding shares of which 18.02 M shares are currently shorted by private and institutional investors with about 14.96 trading days to cover. More on Day One Biopharmaceuticals
Follow Valuation Profit Patterns Odds of Bankruptcy
Check how we calculate scores
Day Stock Highlights
ESG Sustainability
Environmental | Governance | Social |
| President CEO | Jeremy MBA | |||||||||||||||||||||||||||||||||||
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Biotechnology, NASDAQ Composite, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation | ||||||||||||||||||||||||||||||||||||
Financial Strength
| ||||||||||||||||||||||||||||||||||||
Debt LevelsDay One can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Day One's financial leverage. It provides some insight into what part of Day One's total assets is financed by creditors.
| ||||||||||||||||||||||||||||||||||||
Day One Biopharmaceuticals (DAWN) is traded on NASDAQ Exchange in USA. It is located in 2000 Sierra Point Parkway, Brisbane, CA, United States, 94005 and employs 174 people. Day One is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Mid-Cap' category with a current market capitalization of 1.37 B. Day One Biopharmaceu conducts business under Biotechnology sector and is part of Health Care industry. The entity has 100.85 M outstanding shares of which 18.02 M shares are currently shorted by private and institutional investors with about 14.96 trading days to cover.
Day One Biopharmaceuticals currently holds about 394.86 M in cash with (146.85 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 5.38.
Check Day One Probability Of Bankruptcy
Ownership AllocationDay One holds a total of 100.85 Million outstanding shares. The majority of Day One Biopharmaceuticals outstanding shares are owned by other corporate entities. These outside corporations are usually referred to as non-private investors looking to obtain positions in Day One Biopharmaceu to benefit from reduced commissions. Consequently, institutional investors are subject to a different set of regulations than regular investors in Day One. Please pay attention to any change in the institutional holdings of Day One Biopharmaceuticals as this could imply that something significant has changed or is about to change at the company. Also note that almost ten million one hundred ninety-five thousand five hundred thirty-one invesors are currently shorting Day One expressing very little confidence in its future performance.
Check Day Ownership Details
Day Stock Institutional Holders
| Instituion | Recorded On | Shares | |
| T. Rowe Price Associates, Inc. | 2024-06-30 | 2.4 M | |
| Maverick Capital Ltd | 2024-09-30 | 2.1 M | |
| Goldman Sachs Group Inc | 2024-06-30 | 1.9 M | |
| Hhg Plc | 2024-06-30 | 1.8 M | |
| Timessquare Capital Management, Llc | 2024-09-30 | 1.8 M | |
| Geode Capital Management, Llc | 2024-09-30 | 1.4 M | |
| Vestal Point Capital Lp | 2024-06-30 | 1.2 M | |
| Boxer Capital Llc | 2024-09-30 | 1.2 M | |
| First Turn Management Llc | 2024-09-30 | 947.9 K | |
| Ra Capital Management, Llc | 2024-09-30 | 7.9 M | |
| Fmr Inc | 2024-09-30 | 7.4 M |
Day One Historical Income Statement
Day Stock Against Markets
Day One Corporate Management
| PharmD Chiodin | Chief Officer | Profile | |
| Jaa Roberson | Chief Officer | Profile | |
| Elly MD | Chief Officer | Profile | |
| Adam Dubow | General Counsel | Profile | |
| Lauren MBA | Chief Officer | Profile | |
| Adam JD | General Officer | Profile |
Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Day One Biopharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in housing. You can also try the Idea Breakdown module to analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Day One. If investors know Day will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Day One listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.97) | Revenue Per Share 1.144 | Return On Assets (0.25) | Return On Equity (0.18) |
The market value of Day One Biopharmaceu is measured differently than its book value, which is the value of Day that is recorded on the company's balance sheet. Investors also form their own opinion of Day One's value that differs from its market value or its book value, called intrinsic value, which is Day One's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Day One's market value can be influenced by many factors that don't directly affect Day One's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Day One's value and its price as these two are different measures arrived at by different means. Investors typically determine if Day One is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Day One's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.